next-generation sequencing (NGS)

ABL Texcell Diagnostics S.A. (formerly ABL Diagnostics) develops innovative microbiology solutions for improving disease management, including genotyping through NGS and Sanger sequencing, real-time PCR assays, digital analysis software, lab automation, and specimen collection kits.

DNA/RNA extractiongenotypinglab automationReal-time PCRSanger sequencing

Accelevir is a Johns Hopkins University spinout bioanalytical CRO based in Baltimore, Maryland, operating a CAP-accredited, CLIA-certified and BSL-2+ laboratory. It provides molecular, genomic, immunology and bioanalytical testing services supporting cell and gene therapy, biologics and vaccine programs from preclinical studies through Phase 3 and long-term follow-up.

biobankingcell subset isolationcytotoxicity and killing assaysdigital PCR (dPCR)ELISpotFlow Cytometryinfectious sample processing (BSL-2+)LC-MS/MSligand-binding assay (LBA)neutralization assaysPBMC processing and cryopreservationtargeted short- and long-read sequencingT-cell proliferation assays

Aegea Biotechnologies is a life science company in San Diego, CA, focused on nucleic acid technologies for molecular diagnostics. Its patented Switch-Blocker™ chemistry suppresses wild-type DNA and selectively amplifies rare mutations, enabling detection of genetic variants below 0.01% for PCR, NGS, and microarray applications. The company holds 11 issued U.S. patents and offers research-use-only kits and custom assay development.

analytical performance benchmarkingassay design and validationcustom assay developmentMicroarrayPCRqPCR

Ca-Genome Rx leverages ultra-low-cost genomic and transcriptomic sequencing paired with proprietary genomic biomarkers and advanced machine learning tailored for genomics data. Its mission is to empower oncologists and patients with precise, actionable insights that optimize treatment decisions and enhance survival rates and outcomes in the battle against cancer. The company focuses on low-cost omics-based precision oncology and proprietary biomarkers such as Intragenic Rearrangement Burden (IGR) and Tumor-Associated Antigen Burden (TAB).

biomarker discovery and validationgenomic signature analysismachine learning / artificial intelligence for genomics datamulti-omic data analyticsultra-low-cost genomic and transcriptomic sequencing

Clear Labs delivers fully automated next-generation sequencing (NGS) platforms, software, and data analytics for infectious disease and oncology research, plus food safety testing. Its platforms include Clear Dx® for oncology, Clear Ix™ for infectious pathogens, and Clear Safety™ for Listeria and Salmonella sequencing. The company is based in San Carlos, California.

automated bioinformaticsautomated library preparationgenomic surveillanceListeria persistence monitoringpathogen identificationrobotic pipettingSalmonella serotypingwhole genome sequencing (WGS)

EdenRoc Sciences, LLC is a life sciences portfolio company focused on addressing the diseases of aging, with assets ranging from genomic detection to clinical stage pharmaceuticals, forensics and biologic-based consumer products. It founds subsidiaries based on novel science, often intellectual property licensed from top universities, and supports them with shared core business functions. The company is driven by a team of over 100 scientists and staff with support from over 40 advisors.

drug developmentforensic DNA sequencing and genotypinggenomic detectionmicroarray design and fabricationRNA synthesis

Exact Scientific Services, Inc is an ISO 17025 certified analytical laboratory providing chemistry and microbiological testing for food, nutraceutical, environmental, agricultural, and other clients. The company offers food product testing, dietary supplement analysis, water testing, DNA sequencing, and method development, with samples tested the day they are received.

chemistry testingDNA sequencingeDNA analysisGCHPLCmethod validationmicrobiological testingnutritional labelingpathogen analysisPCR analysisproximate analysisshelf-life studieswater metagenomics

GT Molecular develops molecular detection technologies for cancer research and pathogen detection. The company designs ultra-sensitive digital PCR, qPCR, and next-generation sequencing assays, illicit drug detection tests, and end-to-end solutions for cancer genotyping and waterborne pathogen detection, including SARS-CoV-2 wastewater monitoring. It was awarded the CDC's NWSS Multi-Pathogen Assay Development Contract and was recognized by MIT Technology Review as the first lab to identify the SARS-CoV-2 UK variant signature in US sewersheds.

16S rRNA metagenomic sequencingbioinformatics analysiscustom NGS assay design and validationdigital PCR (dPCR)qPCR/RT-qPCRwastewater testing serviceswhole SARS-CoV-2 genome sequencing